Page header

Position of the Transparency Council – Trandate (labetalol)

At its meeting on 25 November 2024, the Transparency Council adopted position No. 134/2024 on the appropriateness of authorising the reimbursement of the drug Trandate (labetalol), for the indication of hypertension in pregnant women

 

Publication of the position >>